Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00732680 · ClinicalTrials.gov registry record · Phase 1
Benefits of the Use of Botox in the Treatment of Empty Nose Syndrome Syndrome
A Phase 1 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00732680: Clinical Trial Phase 1 study, sponsored by Mayo Clinic.
NCT00732680 is a Phase 1 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00732680, a Phase 1 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
Empty Nose Syndrome patients suffer from disabling physical symptoms and considerable distress. To date there is no definitive cure for these symptoms. Established treatment modalities include saline irrigation, surgical implantation of materials or simply use of cotton wads/ silicon cones to simulate the resistive action to airflow of the resected turbinates. This study will research the effectiveness of a new treatment modality in the treatment of Empty Nose Syndrome. This novel treatment method involves the use of botulinum toxin type A (Botox).
Interventions
- DRUG Botulinum Toxin Type A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2008-12 |
| Est. Completion | 2009-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00732680
The ClinicalTrials.gov registry entry for NCT00732680 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Botulinum Toxin Type A is the first listed.
NCT00732680 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00732680 about?
NCT00732680 is a clinical study titled "Benefits of the Use of Botox in the Treatment of Empty Nose Syndrome Syndrome". Empty Nose Syndrome patients suffer from disabling physical symptoms and considerable distress. To date there is no definitive cure for these symptoms. Established treatment modalities include saline irrigation, surgical implantation of materials or simply use of cotton wads/ silicon cones to simula...
What is the current status of trial NCT00732680?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2008-12. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00732680?
The interventions under investigation include: Botulinum Toxin Type A (DRUG).
Who is sponsoring clinical trial NCT00732680?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.